MedTrace Logo

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

NCT00728000 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-11-25

No results posted yet for this study

Summary

The goal of this study is to determine the effect of chemotherapy on decreasing the size of unresectable pancreas cancer thereby allowing it to be surgically removed. In addition, this study may provide information on how tumors behave when exposed to certain types of chemotherapy.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DRUG

Gemcitabine

Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.

DRUG

Oxaliplatin

100mg/m2 IV on days 1 and 15 given over 120 mins.

DRUG

Erlotinib

100mg/day PO on days 1-14 and 15-28

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Leslie Oleksowicz, MD · University of Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00728000 on ClinicalTrials.gov